Haj, F. A., Abdelmalek, M., Senapati, J., Montalban-Bravo, G., Faderl, S., Marrero, W. D., Short, N., Daver, N., DiNardo, C., Masarova, L., Ferrajoli, A., Jabbour, E., Borthakur, G., Garcia-Manero, G., Andreeff, M., Kadia, T., Ravandi, F., Valero, Y. A. (2025). Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS). Blood. https://doi.org/10.1182/blood-2025-1688